November 7, 2019
22nd Century Group Files 2019 Third Quarter Report
22nd Century Builds Strong Momentum for its Very Low Nicotine Content Tobacco and Makes Significant Progress in the Development of…
Pharmaceuticals, Biotechnology and Life Sciences
22nd Century Builds Strong Momentum for its Very Low Nicotine Content Tobacco and Makes Significant Progress in the Development of…
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to…
— Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced…
Opened randomized, Phase 2 clinical trial of cirmtuzumab in combination with ibrutinib in patients with CLL and Phase 1b expansion…
Presentations Include Data from More than Thirty NanoString-Related Abstracts Including Five Using the GeoMx Digital Spatial Profiler SEATTLE–(BUSINESS WIRE)–#SITC–NanoString Technologies,…
Presentations Include Data from More than Thirty NanoString-Related Abstracts Including Five Using the GeoMx Digital Spatial Profiler SEATTLE–(BUSINESS WIRE)–#SITC–NanoString Technologies,…
Presentations Include Data from More than Thirty NanoString-Related Abstracts Including Five Using the GeoMx Digital Spatial Profiler SEATTLE–(BUSINESS WIRE)–#SITC–NanoString Technologies,…
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday,…
SALT LAKE CITY–(BUSINESS WIRE)–PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced…
– BLA submission for AT132 for the treatment of XLMTM on-track for mid-2020; MAA on-track for second half of 2020…